-
Oppilotech awarded Innovate UK grant to expand model of outer wall of bacteria
London, UK, 26th April 2018 / Sciad Newswire / Oppilotech Ltd, a biopharmaceutical company founded to develop safe, first-in-class, antibacterial therapies, announced today it has been selected for funding by Innovate UK – the UK’s innovation agency. Oppilotech has been taking a systems biology approach to building a detailed, sophisticated, experimentally validated, computational network model of the…
-
Synpromics awarded Innovate UK grant to evaluate its inducible promoter platform in collaboration with Lonza Pharma & Biotech
Edinburgh, UK, 23rd April 2018 / Sciad Newswire / Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate…
-
The RSA Group Strengthens Commitment to Swiss Life Sciences
London, UK, 11th April 2018 / Sciad Newswire / The RSA Group, a leading Life Sciences executive search firm, is increasing its commitment to serving clients based in Switzerland. Thomas Schleimer, a Partner at The RSA Group with extensive international search and healthcare experience, will now also be working from the firm’s Basel office as the company…
-
Sciad Communications Announces Corporate Sponsorship of OBN
Sciad Communications, the science, tech and health communications consultancy, is pleased to announce its corporate sponsorship of OBN, the membership organisation supporting the UK’s innovative life sciences companies.
-
British Science Week: Prioritising Public Engagement
This week is British Science Week (9-18th March), an annual 10-day event featuring a range of activities across the country, and providing a great example of the use of technology and interactive activities to engage the public with science.
-
Domainex appoints Dr Bodo Spori as Head of Business Development for Europe
Cambridge, UK, 12th March 2018 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe. His appointment reflects Domainex’s commitment to offering cutting-edge, integrated drug discovery services to an increasing number of customers across Europe, and supporting the discovery…
-
Parkinson’s UK, Selcia, and Cresset collaborate to discover new drug candidates for Parkinson’s
London, Ongar, Cambridge, UK, 8th March 2018 / Sciad Newswire / A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today. The collaboration, formed by leading charity Parkinson’s UK, contract innovation and research organization, Selcia (part of Eurofins), and computational chemistry software and services provider,…
-
Medherant expands team with appointment of David Davies as Head of Development
Coventry, UK, 7th March 2018 / Sciad Newswire / Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its…
-
Riffyn Awarded Its First US Patent for Experiment Design and Data Analytics
Newly patented hypergraph data model solidifies Riffyn’s position in the expanding market for linked-data analytics and AI in biotech and pharmaceutical R&D Oakland, CA, USA, 27th February 2018 / Sciad Newswire / Riffyn, a provider of cloud-based R&D software, announced that the United States Patent Office has granted its patent on a hypergraph data model for experiment…
-
Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccines
Keele, UK, Riyadh, KSA, Stockholm, SE, and Seoul, KR, 26th February 2018 / Sciad Newswire / Prokarium, the UK-based synthetic biology company that has developed Vaxonella, an oral, thermostable vaccine delivery platform, today announced the completion of a $10 million investment round. The new funds will enable the clinical development of groundbreaking vaccines against Chlamydia, C.difficile and enteric…